請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/50518
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 盧子彬(Tzu-Pin Lu),陳人豪(Jen-Hau Chen) | |
dc.contributor.author | Kuan-Yi Lin | en |
dc.contributor.author | 林冠怡 | zh_TW |
dc.date.accessioned | 2021-06-15T12:44:14Z | - |
dc.date.available | 2025-06-29 | |
dc.date.copyright | 2016-08-26 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-07-26 | |
dc.identifier.citation | 參 考 文 獻
1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes research and clinical practice. 2011;94(3):311-21. 2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Research and Clinical Practice. 2010;87(1):4-14. doi: http://dx.doi.org/10.1016/j.diabres.2009.10.007. 3. Jiang YD, Chang CH, Tai TY, Chen JF, Chuang LM. Incidence and prevalence rates of diabetes mellitus in Taiwan: Analysis of the 2000-2009 Nationwide Health Insurance database. Journal of the Formosan Medical Association. 2012;111(11):599-604. doi: 10.1016/j.jfma.2012.09.014. PubMed PMID: WOS:000313472900003. 4. Association AD. 2. Classification and diagnosis of diabetes. Diabetes Care. 2015;38(Supplement 1):S8-S16. 5. Khan GH, Aqil M, Pillai KK, Ahmad MA, Kapur P, Ain MR, et al. Therapeutic adherence: a prospective drug utilization study of oral hypoglycemic in patients with type 2 diabetes mellitus. Asian Pacific Journal of Tropical Disease. 2014;4:S347-S52. 6. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140-9. 7. 蔡世澤. 台灣糖尿病照護現況與省思. 臨床醫學. 2000;45:316-20. 8. Association AD. Economic costs of diabetes in the US in 2012. Diabetes care. 2013;36(4):1033. 9. Amiel S, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabetic Medicine. 2008;25(3):245-54. 10. Bron M, Marynchenko M, Yang H, Yu AP, Wu EQ. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs. Postgraduate medicine. 2012;124(1):124-32. 11. Trachtenbarg DE. Diabetic ketoacidosis. Am Fam Physician. 2005;71(9):1705-14. 12. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. The Lancet. 383(9911):69-82. doi: http://dx.doi.org/10.1016/S0140-6736(13)60591-7. 13. DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-95. 14. Association AD. Standards of medical care in diabetes—2015 abridged for primary care providers. Clinical Diabetes. 2015;33(2):97-111. 15. Sircar M, Bhatia A, Munshi M. Review of Hypoglycemia in the Older Adult: Clinical Implications and Management. Canadian Journal of Diabetes. 2016;40(1):66-72. doi: http://dx.doi.org/10.1016/j.jcjd.2015.10.004. 16. Leese GP, Wang J, Broomhall J, Kelly P, Marsden A, Morrison W, et al. Frequency of Severe Hypoglycemia Requiring Emergency Treatment in Type 1 and Type 2 Diabetes A population-based study of health service resource use. Diabetes care. 2003;26(4):1176-80. 17. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes care. 2003;26(6):1902-12. 18. 王治元, 王惠芳, 田凱仁, 李建興, 李洮俊, 汪宜靜, et al. 低血糖. 中華民國糖尿病衛教學會. 2015;(1):176-88. 19. Cryer P. Hypoglycemia During Therapy of Diabetes. 2015. 20. 張鳳梅, 戴淑華, 林成新, 張慧真. 第二型糖尿病病患發生嚴重低血糖之相關因素探討. 臺灣臨床藥學雜誌. 2014;22(2):67-80. doi: 10.6168/fjcp.2014.2202.01. 21. Su C-C. Etiologies of acute hypoglycemia in a Taiwanese hospital emergency department. The Journal of emergency medicine. 2006;30(3):259-61. 22. Zammitt NN, Frier BM. Hypoglycemia in Type 2 Diabetes Pathophysiology, frequency, and effects of different treatment modalities. Diabetes care. 2005;28(12):2948-61. 23. Hsiao Y-C, Chien M-N. Severe hypoglycemia in type 2 diabetes: a hospital-based retrospective study. J Intern Med Taiwan. 2006;17:73-7. 24. Edridge CL, Dunkley AJ, Bodicoat DH, Rose TC, Gray LJ, Davies MJ, et al. Prevalence and incidence of hypoglycaemia in 532,542 people with Type 2 diabetes on oral therapies and insulin: a systematic review and meta-analysis of population based studies. 2015. 25. Honkasalo MT, Elonheimo OM, Sane T. Severe hypoglycaemia in drug-treated diabetic patients needs attention: A population-based study. Scandinavian Journal of Primary Health Care. 2011;29(3):165-70. doi: 10.3109/02813432.2011.580090. PubMed PMID: WOS:000294870300010. 26. Cariou B, Fontaine P, Eschwege E, Lievre M, Gouet D, Huet D, et al. Frequency and predictors of confirmed hypoglycaemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: Results from the DIALOG study. Diabetes & Metabolism. 2015;41(2):116-25. doi: 10.1016/j.diabet.2014.10.007. PubMed PMID: WOS:000354590700003. 27. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia A nested case-control analysis. Diabetes Care. 2008;31(11):2086-91. doi: 10.2337/dc08-1171. PubMed PMID: WOS:000260565000002. 28. Bruderer S, Bodmer M, Jick S, Bader G, Schlienger R, Meier C. Incidence of and risk factors for severe hypoglycaemia in treated type 2 diabetes mellitus patients in the UK–a nested case–control analysis. Diabetes, Obesity and Metabolism. 2014;16(9):801-11. 29. Bramlage P, Gitt AK, Binz C, Krekler M, Deeg E, Tschöpe D. Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia. Cardiovascular diabetology. 2012;11(1):122. 30. 法務部全球資訊. 老人福利法. http://lawmojgovtw/LawClass/LawAllaspx?PCode=D0050037. 2014. 31. 行政院內政部統計處. 105年第3週內政統計通報(104年底人口結構分析). http://wwwmoigovtw/stat/news_contentaspx?sn=10225&page=1. 2016. 32. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Bmj. 2000;321(7258):405-12. 33. DAROC Clinical Practice Guidelines for Diabetes Care- 2015. Taiwan Diabetes Association of the ROC. 2015. 34. 沈德昌, 顏兆熊. 第 2 型糖尿病藥物治療新知. 臺灣醫界. 2008;51(11):466-71. 35. 林建良, 許惠恒, 沈宜靜. 二甲雙胍類降血糖藥物「Metformin」:過去、現在與未來. 內科學誌. 2013;24(6):477-86. doi: 10.6314/jimt.2013.24(6).06. 36. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Annals of internal medicine. 1999;131(4):281-303. 37. Waring WS. Antidiabetic drugs. Medicine. 2016;44(3):138-40. doi: http://dx.doi.org/10.1016/j.mpmed.2015.12.011. 38. 蔡崇煌, 陳靖棻, 蔡新聲, 黃青真, 林澤銘. 降血糖藥物分類:Diabetes M. 澄清醫護管理雜誌. 2011;7(1):42-51. 39. Salem CB, Fathallah N, Hmouda H, Bouraoui K. Drug-induced hypoglycaemia. Drug safety. 2011;34(1):21-45. 40. Leese GP, Wang J, Broomhall J, Kelly P, Marsden A, Morrison W, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care. 2003;26. doi: 10.2337/diacare.26.4.1176. 41. Turner RC, Holman RR, Cull CA, Stratton IM, Matthews DR, Frighi V, et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-53. PubMed PMID: WOS:000075857300006. 42. Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR. Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia A nested case-control analysis. Diabetes care. 2008;31(11):2086-91. 43. Signorovitch JE, Macaulay D, Diener M, Yan Y, Wu EQ, Gruenberger JB, et al. Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non‐insulin antidiabetes drugs. Diabetes, obesity and metabolism. 2013;15(4):335-41. 44. Anderson M, Powell J, Campbell KM, Taylor JR. Optimal management of type 2 diabetes in patients with increased risk of hypoglycemia. Diabetes, metabolic syndrome and obesity: targets and therapy. 2014;7:85. 45. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. Jama. 2010;303(14):1410-8. 46. Hemmingsen B, Schroll JB, Wetterslev J, Gluud C, Vaag A, Sonne DP, et al. Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. CMAJ open. 2014;2(3):E162-E75. 47. Zhang Z, Lovato J, Battapady H, Davatzikos C, Gerstein HC, Ismail-Beigi F, et al. Effect of hypoglycemia on brain structure in people with type 2 diabetes: epidemiological analysis of the ACCORD-MIND MRI trial. Diabetes care. 2014;37(12):3279-85. 48. Munshi MN, Segal AR, Suhl E, Staum E, Desrochers L, Sternthal A, et al. Frequent hypoglycemia among elderly patients with poor glycemic control. Archives of internal medicine. 2011;171(4):362-4. 49. Ginde AA, Espinola JA, Camargo CA. Trends and disparities in US emergency department visits for hypoglycemia, 1993–2005. Diabetes Care. 2008;31(3):511-3. 50. Group UPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet. 1998;352(9131):837-53. 51. Bolen S, Feldman L, Vassy J, Wilson L, Yeh H-C, Marinopoulos S, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Annals of internal medicine. 2007;147(6):386-99. 52. Association AD. 7. Approaches to glycemic treatment. Diabetes Care. 2015;38(Supplement 1):S41-S8. 53. Hsu JC, Ross-Degnan D, Wagner AK, Cheng C-L, Yang Y-HK, Zhang F, et al. Utilization of oral antidiabetic medications in Taiwan following strategies to promote access to medicines for chronic diseases in community pharmacies. Journal of pharmaceutical policy and practice. 2015;8(1):15. 54. Chang C-H, Jiang Y-D, Chung C-H, Ho L-T, Chuang L-M. National trends in anti-diabetic treatment in Taiwan, 2000–2009. Journal of the Formosan Medical Association. 2012;111(11):617-24. 55. Hampp C, Borders-Hemphill V, Moeny DG, Wysowski DK. Use of antidiabetic drugs in the US, 2003–2012. Diabetes care. 2014;37(5):1367-74. 56. Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Annals of internal medicine. 2012;156(3):218-31. 57. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. Bmj. 2012;344. 58. 衛生福利部統計處. 103年死因統計結果分析. http://wwwmohwgovtw/CHT/DOS/Statisticaspx?f_list_no=312&fod_list_no=5488. 2014. 59. Boucai L, Southern WN, Zonszein J. Hypoglycemia-associated mortality is not drug-associated but linked to comorbidities. The American journal of medicine. 2011;124(11):1028-35. 60. 許惠恒. 低血糖與認知功能障礙. 當代醫學. 2013;(471):7-9. 61. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes care. 2010;33(6):1389-94. 62. Clemens KK, Shariff S, Liu K, Hramiak I, Mahon JL, McArthur E, et al. Trends in Antihyperglycemic Medication Prescriptions and Hypoglycemia in Older Adults: 2002-2013. PloS one. 2015;10(9):e0137596. 63. Purnell TS, Joy S, Little E, Bridges JF, Maruthur N. Patient preferences for noninsulin diabetes medications: a systematic review. Diabetes care. 2014;37(7):2055-62. 64. Czech M, Rdzanek E, Pawęska J, Adamowicz-Sidor O, Niewada M, Jakubczyk M. Drug-related risk of severe hypoglycaemia in observational studies: a systematic review and meta-analysis. BMC endocrine disorders. 2015;15(1):57. 65. Henderson J, Allen K, Deary I, Frier B. Hypoglycaemia in insulin‐treated Type 2 diabetes: frequency, symptoms and impaired awareness. Diabetic Medicine. 2003;20(12):1016-21. 66. 衛生福利部中央健康保險署. 全民健康保險醫療品質資訊公開網頁. http://wwwnhigovtw/AmountInfoWeb/iDescaspx?rtype=2&Q5C2_ID=889. 2016. 67. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. Journal of Clinical Epidemiology. 1992;45(6):613-9. doi: http://dx.doi.org/10.1016/0895-4356(92)90133-8. 68. 朱育增, 吳肖琪, 李玉春, 賴美淑, 譚醒朝. 探討共病測量方法於健保次級資料之應用. 臺灣公共衛生雜誌. 2010;29(3):191-200. doi: 10.6288/tjph2010-29-03-01. 69. 朱育增, 吳肖琪. 回顧與探討次級資料適用之共病測量方法. A Review of claims-based Comorbidity Measures] 臺灣公共衛生雜誌. 2010;29(1):8-21. 70. Cheng T-M. Taiwan’s new national health insurance program: genesis and experience so far. Health Affairs. 2003;22(3):61-76. 71. Lin C-C, Lai M-S, Syu C-Y, Chang S-C, Tseng F-Y. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. Journal of the Formosan Medical Association. 2005;104(3):157-63. 72. 朱俊源, 李文賢, 許柏超, 蘇河名, 林宗憲, 溫文才, et al. 以心臟科醫師的角度來看糖尿病藥物的使用. 內科學誌. 2013;24(1):12-8. 73. Zhang L, Ji L, Guo L, Lu J, Tian H, Zhu D, et al. Treatment Patterns and Glycemic Control in Older Adults with Type 2 Diabetes Mellitus Receiving Only Oral Antidiabetes Drugs in China. Diabetes technology & therapeutics. 2015;17(11):816-24. 74. Schloot NC, Haupt A, Schütt M, Badenhoop K, Laimer M, Nicolay C, et al. Risk of severe hypoglycemia in sulfonylurea‐treated patients from diabetes centers in Germany/Austria: How big is the problem? Which patients are at risk? Diabetes/Metabolism Research and Reviews. 2015. 75. van Keulen K, van der Linden PD, Souverein PC, Heerdink ER, Egberts AC, Knol W. Risk of Hospitalization for Hypoglycemia in Older Patients with Diabetes Using Antipsychotic Drugs. The American Journal of Geriatric Psychiatry. 2015;23(11):1144-53. 76. Jafari B, Britton ME. Hypoglycaemia in elderly patients with type 2 diabetes mellitus: a review of risk factors, consequences and prevention. Journal of Pharmacy Practice and Research. 2015;45(4):459-69. 77. Chan SP, Colagiuri S. Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. Diabetes Research and Clinical Practice. 2015. doi: http://dx.doi.org/10.1016/j.diabres.2015.07.002. 78. Ha WC, Oh SJ, Kim JH, Lee JM, Chang SA, Sohn TS, et al. Severe hypoglycemia is a serious complication and becoming an economic burden in diabetes. Diabetes & metabolism journal. 2012;36(4):280-4. 79. Chen Y-J, Yang C-C, Huang L-C, Chen L, Hwu C-M. Increasing trend in emergency department visits for hypoglycemia from patients with type 2 diabetes mellitus in Taiwan. Primary Care Diabetes. 2015;9(6):490-6. doi: http://dx.doi.org/10.1016/j.pcd.2015.04.002. 80. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Archives of internal medicine. 1997;157(15):1681-6. 81. Banarer S, Cryer PE. Hypoglycemia in type 2 diabetes. Medical Clinics of North America. 2004;88(4):1107-16. 82. Abdelhafiz AH, Rodríguez-Mañas L, Morley JE, Sinclair AJ. Hypoglycemia in Older People-A Less Well Recognized Risk Factor for Frailty. Aging and disease. 2015;6(2):156. 83. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA. 1997;278(1):40-3. 84. Harper W, Clement M, Goldenberg R, Hanna A, Main A, Retnakaran R, et al. Pharmacologic Management of Type 2 Diabetes. Canadian Journal of Diabetes. 2013;37, Supplement 1:S61-S8. doi: http://dx.doi.org/10.1016/j.jcjd.2013.01.021. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/50518 | - |
dc.description.abstract | 目的
嚴重低血糖是第二型糖尿病患者的重要副作用,其可能增加病患生理與心理及經濟的負擔,過去已知不同的藥物使用可能使得病患具有產生嚴重低血糖的不同風險值,因此本論文運用美國糖尿病治療指引作為藥物分類的參考依據,進一步釐清在何種藥物組合下第二型糖尿病患會有較高的嚴重低血糖風險。 方法 本研究使用國家衛生研究院全民健康保險研究資料庫承保抽樣百萬歸人檔,探討2008年至2011年第二型糖尿病患且使用藥物之新發病患,分析索引日期前不同藥物治療方式罹患嚴重低血糖的風險。嚴重低血糖病患的索引日期定義為在研究期間內發生嚴重低血糖住院或尋求協助之時間,而對照組的索引日期則定義為病患在研究日期的最後一天追蹤日期。為了探索不同的藥物組合是否具有誘發嚴重低血糖不一樣的風險情形,我們使用Cox風險模型進行分析。 結果 經過一連串篩選條件以及傾向分數配對後,本研究納入的分析族群共有嚴重低血糖204人,對照組816人。在控制性別、年齡、病齡及察爾森共病指數等干擾變項後,統計分析結果顯示第二型糖尿病病患使用胰島素合併其它藥物發生嚴重低血糖的風險最高,其勝算比為9.63(4.40-21.08),若進一步將病患根據年齡切割成不同族群,結果顯示≧65歲之老年病患在使用胰島素合併其它藥物發生嚴重低血糖的風險最高,其勝算比為12.67(4.15-38.62)。 結論 本論文使用健保資料庫分析之第二型糖尿病族群以使用口服藥物者較多,而發生嚴重低血糖之病患則大多使用合併藥物,藥物組合中則以使用胰島素合併其它藥物發生嚴重低血糖風險最高,同樣的情形可以在年齡≧65歲的病患上觀察到。因此,未來針對使用胰島素合併其他藥物之第二型糖尿病病患應加強其衛教,以減少嚴重低血糖副作用之發生。 | zh_TW |
dc.description.abstract | Objective
Severe hypoglycemia is a severe side effect of type 2 diabetes (T2D), which is able to increase the burden of psychological, physiological and economy in the patients. To address which populations of T2D patients are susceptible to severe hypoglycemia, we classified the T2D patients into different groups based on the clinical guidelines developed by the American Diabetes Association. Specifically, this study aims to explore the causal associations between the combinations of antidiabetic drugs and severe hypoglycemia. Methods We used the data collected from the National Health Insurance Research database (NHIRD) during 2008-2011 in Taiwan. This study employed a nested case-control study design to investigate the newly diagnosed T2D patients. Severe hypoglycemia case group was defined as the patients underwent the hypoglycemia and sought the help from a hospital. For the case group, the date for the hospitalization or the event was called as the index date; whereas, for the control group, the last day of the following day in the studied period was defined as the index date. To analyze the associations of the combinations of drugs and severe hypoglycemia, a Cox hazard regression model was utilized. Results To minimize the potential biases from confounding factors, we matched the case group by using the propensity score method based on the one to fourth design. The results revealed 204 cases with severe hypoglycemia and 816 matched controls. Statistical analysis of the associations between drug combinations and hypoglycemia revealed the highest odds ratio (9.63, 95% CI: 4.40-21.08) in the T2D patients concurrently using insulin and other drugs. Similar high odds ratio (12.67, 95% CI: 4.15-38.62) was observed in the elder T2D patients, whose age was higher than 65. Conclusion The results of this study indicated that the T2D patients from the NHIRD had a higher proportion to take oral drugs and intriguingly most patients in the case group of hypoglycemia used multiple drugs simultaneously. The statistical results showed that the T2D patients had the highest odds ratio while concurrently using insulin and other drugs. The same phenomenon can be observed in the elder T2D patients, whose age was higher than 65. Consequently, we shall provide detailed health education for the T2D patients to prevent the occurrence of hypoglycemia while they concurrently use insulin and other drugs. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T12:44:14Z (GMT). No. of bitstreams: 1 ntu-105-R03847004-1.pdf: 1480472 bytes, checksum: 5005d250981502525ad962f88558e9cd (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 目 錄
口試委員會審定書 i 謝辭 ii 中文摘要 iii 英文摘要 v 第一章 緒論 1 第一節 研究背景與動機 1 第二節 嚴重低血糖的定義、導因與相關因素 4 第三節 糖尿病藥物治療 5 第四節 治療方式與嚴重低血糖 9 第五節 研究的重要性 12 第二章 研究方法 14 第一節 研究架構 14 第二節 資料來源與研究對象 15 第三節 變項操作型定義 17 第四節 資料分析 20 第三章 研究結果 21 第一節 嚴重低血糖組與對照組之建立 21 第二節 病患基本人口學變項之分析 21 第三節 第二型糖尿病患不同藥物治療方式與嚴重低血糖之風險相關性 22 第四節 不同年齡、性別與慢性疾病之治療方式與嚴重低血糖之相關性 23 第五節 不同累積用藥時間之治療方式趨勢與低血糖之相關性 25 第四章 討論 27 參 考 文 獻 51 | |
dc.language.iso | zh-TW | |
dc.title | 第二型糖尿病患者不同藥物治療方式對罹患嚴重低血糖影響 | zh_TW |
dc.title | Different drug treatments may induce severe hypoglycemia to type 2 diabetes mellitus patients | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 林敬恒(Ching-Heng Lin) | |
dc.contributor.oralexamcommittee | 蕭自宏(Tzu-Hung Hsiao) | |
dc.subject.keyword | 第二型糖尿病,合併症,嚴重低血糖,糖尿病藥物,老年人, | zh_TW |
dc.subject.keyword | complication,severe hypoglycemia,older patients,anti-diabetic drugs,type 2 diabetes, | en |
dc.relation.page | 57 | |
dc.identifier.doi | 10.6342/NTU201601305 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2016-07-26 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 公共衛生碩士學位學程 | zh_TW |
顯示於系所單位: | 公共衛生碩士學位學程 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf 目前未授權公開取用 | 1.45 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。